All In MedTech

FDA Clearance Tracker · P140017-S004

ENSEMBLE II TRANSCATHETER VALVE DELIVERY SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 12, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 12, 2016

Approved

Time to decision

140 days

Received Apr 25, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

The decision

FDA number
P140017-S004
Device name
ENSEMBLE II TRANSCATHETER VALVE DELIVERY SYSTEM
Applicant location
Mounds View, MN
Received
Apr 25, 2016
Decided
Sep 12, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P140017

Device type

Every decision under product code NPV

FDA's approval statement

As written in FDA's record.

Approval for a product line extension to the Ensemble Transcatheter Valve Delivery System.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.